Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.

Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N; Jikei Heart Study group..

Lancet. 2007 Apr 28;369(9571):1431-9. Retraction in: Lancet. 2013 Sep 7;382(9895):843.

PMID:
17467513
2.

JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.

Mochizuki S, Shimizu M, Taniguchi I, Kanae K, Yoshida S, Tajima N, Dahlöf B; JIKEI HEART Study Group..

Cardiovasc Drugs Ther. 2004 Jul;18(4):305-9.

PMID:
15367828
3.

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.

Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group..

Eur Heart J. 2009 Oct;30(20):2461-9. doi: 10.1093/eurheartj/ehp363. Epub 2009 Aug 31. Retraction in: Eur Heart J. 2013 Apr;34(14):1023.

PMID:
19723695
4.

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators..

Lancet. 2007 Jun 23;369(9579):2079-87.

PMID:
17586303
5.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group..

Lancet. 2004 Jun 19;363(9426):2022-31.

PMID:
15207952
6.

Concerns about the Jikei Heart Study.

Yui Y.

Lancet. 2012 Apr 14;379(9824):e48. doi: 10.1016/S0140-6736(12)60599-6. No abstract available.

PMID:
22500880
7.

The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).

Yamazaki T, Kohro T, Chujo M, Ishigaki M, Hashimoto T.

Hypertens Res. 2013 Feb;36(2):140-50. doi: 10.1038/hr.2012.154. Epub 2012 Oct 25.

PMID:
23096231
8.

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A.

Lancet. 2007 Jul 21;370(9583):221-9. Erratum in: Lancet. 2007 Nov 3;370(9598):1542.

PMID:
17658393
9.

Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.

Muramatsu T, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, Ichimiya S, Ohno M, Sone T, Ikeda N, Watarai M, Murohara T; NAGOYA HEART Study Investigators..

Hypertension. 2012 Mar;59(3):580-6. doi: 10.1161/HYPERTENSIONAHA.111.184226. Epub 2012 Jan 9. Erratum in: Hypertension. 2015 Jul;66(1):e1.

11.

Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study.

Yoshida H, Shimizu M, Ikewaki K, Taniguchi I, Tada N, Yoshimura M, Rosano G, Dahlöf B, Mochizuki S; Jikei Heart Study group..

J Hypertens. 2010 Jun;28(6):1150-7. doi: 10.1097/HJH.0b013e328338a8b6. Retraction in: J Hypertens. 2013 Nov;31(11):2324.

PMID:
20467269
13.
15.

Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).

Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H; Kyoto Heart Study Group..

Am J Cardiol. 2012 May 1;109(9):1308-14. doi: 10.1016/j.amjcard.2011.12.025. Epub 2012 Feb 9.

PMID:
22325086
16.
17.

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.

Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study..

Clin Ther. 2004 Jun;26(6):855-65. Erratum in: Clin Ther. 2004 Jul;26(7):1185. Clin Ther. 2005 Jan;27(1):142.

PMID:
15262456
18.

Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.

Sawada T, Takahashi T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group..

J Hum Hypertens. 2009 Mar;23(3):188-95. doi: 10.1038/jhh.2008.116. Epub 2008 Sep 18. Erratum in: J Hum Hypertens. 2013 Sep;27(9):580.

PMID:
18800142
19.

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP.

Lancet. 2010 Apr 10;375(9722):1255-66. doi: 10.1016/S0140-6736(09)61966-8. Epub 2010 Mar 16.

PMID:
20236700
20.

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators..

N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

Supplemental Content

Support Center